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Background: Cancer metastasis caused by circulating tumor cells (CTCs) accounts for 90% cancer-related death
worldwide. Blocking the circulation of CTCs in bloodstream and their hetero-adhesion to vascular endothelia of the
distant metastatic organs may prevent cancer metastasis. Nanomaterial-based intervention with adhesion between
CTCs and endothelia has not been reported. Driven by the novel idea that multivalent conjugation of EpCAM and
Slex antibodies to dendrimer surface may enhance the capacity and specificity of the nanomaterial conjugates for
capturing and down-regulating colorectal CTCs, we conjugated the dendrimer nanomaterial with the EpCAM and
Slex antibodies, and examined the capacity of the dual antibody-coated nanomaterial for their roles in interrupting
CTCs-related cancer metastasis.
Results: The antibody-coated nanomaterial was synthesized and characterized. The conjugates specifically bound
and captured colon cancer cells SW620. The conjugate inhibited the cells’ viability and their adhesion to fibronectin
(Fn)-coated substrate or human umbilical vein endothelial cells (HUVECs) in a concentration-dependent manner. In
comparison with SW480 and LoVo cell lines, the activity and adhesion of SW620 to Fn-coated substrate and HUVECs
were more specifically inhibited by the dual antibody conjugate because of the higher levels of EpCAM and Slex on
SW620 cell surface. The hetero-adhesion between SW620 and Fn-coated substrate, or HUVECs was inhibited by
about 60-70%. The dual conjugate showed the inhibition capacity more significant than its corresponding single
antibody conjugates.
Conclusions: The present study provides the new evidence that coating nanomaterials with more than one
antibody against CTCs may effectively interfere with the interaction between SW620 and HUVECs.
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Cancer is the second killer that leads people to death
worldwide [1,2]. It was found that cancer metastasis was
the principal cause of death among cancer patients [3-5].
The presence of circulating tumor cells (CTCs) [6-8], which
are detached from primary tumor and enter the blood-
stream [9], may contribute to initiate cancer metastasis.
The progress of cancer metastasis usually depends on a
series of consequential events, including the activation of
dormant CTCs, the hetero-adhesion of CTCs to vascular
endothelial bed of secondary organs, the continued survival
and proliferation of CTCs after extravasation, and the for-
mation of initial micrometastatic foci [10]. It seems that the
effective prevention of cancer metastasis may be achieved
by interrupting the circulation or activation of CTCs in
blood and/or inhibiting the adhesion between CTCs and
vascular endothelial cells.
CTCs as the hallmark of cancer metastasis have been
paid more attention. To effectively interfere with the
CTCs-related cancer metastasis, the residual CTCs should
be preferentially captured and restrained with the en-
hanced specificity [11]. However, owing to the low num-
ber of CTCs in blood [12,13], capturing CTCs is a great
technological challenge. Current chemotherapeutics and
nanomaterials-based drug delivery system are designed to
kill the malignant cancer cells, not CTCs per se. The ser-
ious adverse effects resulted in the damaged normal tis-
sues and the decreased immunity [14,15]. Once CTCs in
bloodstream were activated, cancer metastasis will be ir-
revocably initiated [16,17]. Some techniques were devel-
oped to capture CTCs, such as employing the epithelial
cell adhesion molecule (EpCAM) antibody-coated three-
dimensional nanostructured substrates [18,19], dendrimers
[20], graphene oxide nanosheets [21] or immunomagnetic
nanospheres [20,22,23]. However, these studies were only
confined to functionalize nanomaterials with one targeting
antibody against a single CTCs surface biomarker. Besides,
the abundance of one biomarker varies dynamically with
the cell cycle [24,25]. The level and activity of EpCAM
expressed by CTCs not by hematologic cells was decreased
with the epithelial-to-mesenchymal transition [26-28].
Therefore, the weak binding affinity of nanomaterials as-
sembling one targeting antibody can't assure the extremely
exact capture of CTCs. The unbound CTCs still made it
possible to drive cancer metastasis.
Adhesion of CTCs to vascular endothelium was another
crucial point of CTCs-derived cancer metastasis. Our previ-
ous studies demonstrated that chemopreventives such as
S-nitrosocaptopril (CAP-NO) [10] and Metapristone (the
metabolite of mifepristone) [29] with the low cytotoxicity
had the intervention effects on the adhesion and invasion
of colorectal CTCs to human umbilical vein endothelial
cells (HUVECs). These related research laid the technical
foundation for our study. Considering the fact that EpCAM[30,31] and saliva acidifying louis oligosaccharides (Sialyl
Lewis X, Slex) [32,33] are over-expressed on the surface of
colorectal CTCs in circulation [32]. EpCAM antibody (anti-
EpCAM) can directly interfere the adhesion process of
CTCs [34] while Slex antibody (antiSlex) can indirectly
block the adhesion between CTCs and endothelial cells
through Slex/E-selection interaction [35,36]. Dendrimers-
mediated multivalent binding effects were also exploited in
previous studies [20]. Thus, we hypothesize that multivalent
conjugation of both antiEpCAM and antiSlex to nanoscale
polyamidoamine (PAMAM) dendrimers may significantly
improve the anti-proliferation and anti-adhesion effects by
enhancing the capture specificity, increasing the binding af-
finity, and avoiding the non-specific binding to similar cell
subpopulations.
To test the hypothesis, we, herein, showed a novel strat-
egy to realize the highly-specific binding, the restraint of
colorectal CTCs, and the inhibition of adhesion of CTCs to
vascular endothelial cells in vitro by using the bioconjugates
that combine PAMAM dendrimers with dual targeting
antibodies (antiEpCAM and antiSlex). Though attachment
of both E-selectin and antiEpCAM to the functionalized
glass substrates were previously reported [34], we, for the
first time, showed conjugation of both antiEpCAM and
antiSlex to dendrimers as one entity and its physicochemi-
cal characterization in this study. The dual roles of the bio-
conjugates in cancer metastasis prevention, including
restraining the captured CTCs and inhibiting their adhe-
sion, were also demonstrated here.
Results
Synthesis and physiochemical characterization of
G6-5A-5S and PE-5A-G6-5S-FITC conjugates
Nanostructured PAMAM dendrimers with the func-
tional group of 256 end amines were chosen as the good
scaffolds to assemble dual antibodies, owing to their
high payload and multivalent binding effect [20,37].
AntiEpCAM and/or antiSlex antibodies were sequen-
tially conjugated onto the completely carboxylated G6
PAMAM (CC G6) dendrimer surface as previously re-
ported [20]. Fluorescence-labeled dual antibody conju-
gate was similarly synthesized by using phycoerythrin
(PE) linked antiEpCAM (antiEpCAM-PE) and fluores-
cein isothiocyanate (FITC) linked antiSlex (antiSlex-
FITC, i.e., antiSlex and IgG/IgM-FITC antibodies were
used together and abbreviated as antiSlex-FITC here-
after), instead (Figure 1a). The resultant antibody conju-
gates were used for the following cancer metastasis
prevention assays including cell binding, cell activity
regulation and cell adhesion (Figure 1a). For PE-5A-G6-
5S-FITC conjugate in aqueous solution, fluorescence
images taken at λex 488 and 543 nm demonstrated each
antibody was coated on the modified dendrimer surface
(Figure 1b). For G6-5A-5S conjugate, field emission
Figure 1 Synthesis and physiochemical characterization of dendrimers assembling with antiEpCAM and antiSlex with or without fluorescence
labeling. a, Schematic illustration of the construction of dual antibody-conjugated dendrimers for exploring their biological functions in cancer metastasis
through binding the target cancer cells. b, Images of PE-5A-G6-5S-FITC conjugate in aqueous solution under a laser confocal microscope. c, A FSEM image
of the dry conjugate G6-5A-5S. d, The ultraviolet absorption spectra of CC G6 dendrimers, antibody and dual antibody conjugates in PBS (pH 7.4) solution.
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showed its characteristic morphology of round pie with
the particle size of 100 nm (Figure 1c). UV spectra
analysis at λ220 nm indicated the successful coating of
dendrimers with antibodies in comparison with the
non-absorption of CC G6 dendrimers (Figure 1d).CTCs bound and captured by the conjugate
Considering colon cancer cell lines including SW480,
SW620 and LoVo express different levels of biomarkers
(e.g., EpCAM), which was confirmed by the flow cytometry
(Additional file 1: Figure S1), the binding and capture cap-
ability of antiEpCAM and antiSlex sequentially-conjugated
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EpCAM and Slex-expressing colon cancer cell lines was in-
dividually investigated by us.Specificity in recognizing and binding the adherent cells
Preliminary experiments indicated that G6-5A-5S con-
jugate could efficiently bind the target cells within 1 h
(Additional file 1: Figure S2). To qualitatively evaluate
the binding effects of G6-5A-5S conjugate at various
concentrations on the three adherent colon cancer cell
lines, laser confocal microscope analysis was performed.
The cell nucleus was labeled with blue color to distin-
guish other cell components. Once cells were recog-
nized and bound by PE-5A-G6-5S-FITC conjugate, the
merged yellow-green color was displayed in cellular
membrane. Fluorescence intensity was concentration-
dependently increased with the conjugate increased
from 10 to 20 μg mL−1. Moreover, fluorescence intensity
from the cytomembrane of SW620 cells was more
stronger than that from LoVo and SW480 cell lines
(Figure 2). It seemed that the conjugate was more inter-
nalized in SW620 cell than in SW480 and LoVo cell
lines through the double specific antigen-antibody
interactions.Figure 2 Fluorescence micrographs of the adherent colon cancer cell lines
conjugate at various concentrations (0, 10, 20 μg mL−1). Cell nucleus was sta
with the merged yellow-green color (positive to both FITC and PE).Efficiency in capturing the suspensory cells
The metastatic ability of non-adherent CTCs [38] may
differ from that of adherent CTCs [39]. To further
evaluate the capture capability of PE-5A-G6-5S-FITC
conjugate (20 μg mL−1) to the suspensory cell lines,
fluorescence inverted microscope and flow cytometric
analyses were both carried out. The cell lines have iden-
tical exposure time (1 h) and baseline of fluorescence in-
tensity. Without the non-specific binding, the conjugate
showed the specific receptor-mediated binding to both
SW620 and LoVo cell lines, which was seen from the
distinct yellow-green fluorescence on cytomembrane.
The increased fluorescence intensity was displayed on
SW620 cell than on LoVo cell. The number of captured
SW620 cells seemed to be more than that of captured
LoVo cells in any random visual field (Figure 3a). The
capture efficiency of the conjugate was also quantita-
tively evaluated by the % FITC and PE-positive cells
within Q2 quadrant analyzed by the flow cytometry.
Relative to the isotype control, the capture efficiency for
SW620 cells was 4-fold higher than that for LoVo cells
based on the captured numbers (Figure 3b). The en-
hanced capture efficiency for SW620 cells might be up
to the relatively higher expression levels of EpCAM and
Slex (Additional file 1: Figure S1).(SW620, SW480 and LoVo) respectively bound by PE-5A-G6-5S-FITC
ined with blue color (positive to DAPI) while cell membrane was labeled
Figure 3 Qualitative and quantitative analyses of the suspensory SW620 and LoVo cell lines respectively captured by PE-5A-G6-5S-FITC
conjugate at the same concentration of 20 μg mL−1. a, Representative fluorescence images of the captured cell lines at different excitation
channels. b, Flow cytometric analysis of the capture efficiency of the conjugate in comparison with the isotype control.
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conjugate
Once cancer cells were captured, the interactions be-
tween single or dual antibody conjugates and cell lines
were investigated by us in parallel as follows.
Inhibition of the proliferation of captured cells
The effects of single and dual antibody conjugates (G6-
5A, G6-5S, G6-5A-5S) on the proliferation of captured
cells were studied first of all. 48 h of binding treatment re-
sulted in the decreased cell viability relative to control.
With the concentration of conjugate increased from 1.25
to 20 μg mL−1, the cell activity of each cell line was
concentration-dependently restrained (Figure 4a-c). The
cell viability caused by single and dual antibody conjugates
was compared to that by CC G6 dendrimers. CC G6 den-
drimers remained more than 80% of cell viability even at
the concentration of 20 μg mL−1. After single or dual anti-
body was conjugated onto dendrimer surface, the viability
of each cancer cell line was obviously decreased. The
single or dual antibody conjugate showed the stronger in-
hibitory effect on SW620 than on LoVo and SW480 cell
lines. For example, the cell activity of SW620, LoVo and
SW480 was reduced to 51.24%, 60.22% and 62.93%, respect-
ively, by G6-5A conjugate (20 μg mL−1) (Figure 4a-c). Itseemed that conjugates produced the inhibitory but not the
lethal effects. The high levels of EpCAM and Slex might
contribute to the selectivity of the conjugates for SW620
cells. G6-5A-5S and G6-5A conjugates had the stronger
capability of restraining the activity of the same cells com-
pared to G6-5S conjugate (Figure 4a-c). The decreased cell
activity might be mainly attributed to the presence of
EpCAM on cancer cells. The down-regulation of the cap-
tured colon cancer cell lines indicated that dual antibody-
coated dendrimers may fit into a new class of therapeutic
for preventing cancer metastasis by selectively restraining
target CTCs rather than non-selectively killing normal and
cancer cells.
Flow cytometric analysis of cell cycle distribution
To further explore how the G6-5A-5S conjugate affected
the cell activity, cell cycle distribution was analyzed by
flow cytometry. Cell lines after individual incubation with
the conjugate for 48 h were stained with propidium iodide
(PI) staining to determine the cell population in every
phases of G0/G1, S and G2/M. Flow cytometric images
showed that the conjugate could cause a concentration-
dependent increase in cell population of the G0/G1 phase
and a decrease in cell population of the S phase without a
significant increase in cell population of the G2/M phase
Figure 4 Decrease in viability of colon cancer cell lines induced by single and dual antibody conjugates at concentrations ranging
from 1.25 to 20 μg mL−1. a, SW480 cells; b, LoVo cells; c, SW620 cells.
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was found for SW480 cells. The significance between
SW480 and SW620 cell lines indicated the increased
inhibitory effect of conjugate on SW620 cells. However,
for LoVo cells, the cell population in G2/M phase was
concentration-dependently increased and that in S
phase was decreased without a significant change in
G0/G1 phase (Figure 5b), suggesting that dual antibody
conjugate G6-5A-5S mainly arrested SW480 and SW620
cell lines at the G0/G1 stage and LoVo cells at the G2/
M stage. The difference in cell cycle distribution might
be attributed to the different interaction mechanism be-
tween dual antibody conjugate and each colon cancer
cell line.Cellular mitochondrial membrane potential (MMP)
evaluation
MMP (Δψm) depolarization is a prelude of cell apoptosis.
The effects on cellular Δψm induced by various concen-
trations of G6-5A-5S conjugate (0, 10, 20 μg mL−1) weremeasured with DiOC6(3) (3,3’-Dihexyloxacarbocyanine
iodide) staining. The increased fluorescence intensity pre-
dicts the decreased Δψm. Flow cytometric analysis showed
that fluorescence intensity from the treated SW620 cells
was stronger than that from the untreated ones. The cellular
Δψm was decreased in a moderate concentration-dependent
manner. However, the conjugate at the concentration up to
20 μg mL−1 only produced 15% loss of Δψm. In contrast,
the MMP of treated SW480 and LoVo cell lines wasn’t sig-
nificantly affected by the conjugate, indicating the mitochon-
drial function and electron transport chain activity are kept
intact (Figure 5c). It seems like that the dual antibody-
coated dendrimer conjugate could result in the change of
cellular MMP.Inhibition of the adhesion of cancer cells by the conjugate
We performed the related adhesion assays as follows by
using the conjugate at the safe concentrations ranging
from 1.25, 2.5, 5 to 10 μg mL−1 to determine whether
the single and dual antibody conjugates could intervene
Figure 5 Cell cycle distribution and cellular MMP of colon cancer cell lines after exposure to dual antibody conjugate G6-5A-5S at 10 and
20 μg mL−1. a, DNA flow cytometric images of the treated SW620 cells with the conjugate. b, Percentage of cell population in every stage (G0/G1, S
and G2/M). c, The influence of conjugate on the cellular MMP. The increased fluorescence intensity of DiOC6(3) usually indicated the decreased MMP.
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cer metastasis prevention.
Substrate adhesion analysis
EpCAM and Slex are two adhesion molecules expressed by
CTCs not by hematologic cells [40-42]. E-selectin was
mainly expressed on the activated endothelial cell surface of
blood vessels. The interaction between Slex and E-selectin
mediated the hetero-adhesion of CTCs to vascular endothe-
lial cells and the continued survival and proliferation of
CTCs [35,36]. Conjugation of antiEpCAM and/or antiSlex
antibodies onto the dendrimer surface might effectively
interfere the hetero-adhesion of cancer cells to basement
membrane and endothelial cells. Similar MTT {[3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrasodium bromide] tetra-
zolium salt} assay was used to evaluate the inhibitory effects
of G6-5A, G6-5S and G6-5A-5S conjugates on the adhesion
of colon cancer cell lines to fibronectin (Fn)-coated artificial
substrate membrane. CC G6 dendrimers used as the con-
trols were also tested to demonstrate their low effects in ad-
hesion process. In contrast, the antibody conjugates could
lead to the reduced adhesion between cancer cells and Fn
with concentrations increased from 1.25 to 10 μg mL−1. The
adhesive percentage of SW480, LoVo and SW620 cell lines
was 74.20%, 34.30% and 32.93%, respectively, with the G6-
5A-5S conjugate at 10 μg mL−1 (Figure 6a-c). It was seenthat the conjugate was not effective in blocking the adhesion
of SW480 cells but the adhesion of SW620 and LoVo cell
lines to Fn. In comparison with single antibody conjugates
G6-5A and G6-5S, dual antibody conjugate G6-5A-5S
showed the stronger interference ability (Figure 6a-c). For
LoVo cells, the mean anti-adhesion efficacy of G6-5S, G6-
5A and G6-5A-5S were 44.90%, 61.09% and 65.70%, respect-
ively (Figure 6b), suggesting that antiEpCAM and antiSlex
antibodies might play the synergistic effects in inhibiting the
adhesion of cancer cells to Fn-coated substrates, and the
antiEpCAM was the key factor with this respect.
HUVECs adhesion analysis
Hetero-adhesion of CTCs to local vascular endothelium
initiates the irreversible cancer metastasis. Using the tar-
geting antibodies-coated nanomaterials to interfere the
adhesion process will be a new attempt. In this assay,
fluorescence microscopic analysis was performed to assess
the anti-adhesion effects of single and dual antibody
conjugates (G6-5A, G6-5S and G6-5A-5S). The hetero-
adhesion of three colon cancer cell lines to HUVECs was
individually inhibited by the conjugates in a concentration-
dependent manner (Figure 7a-c), for example, the number
of SW480 cells with green fluorescence that adhered to
HUVECs was concentration-dependently decreased by G6-
5A-5S from 1.25 to 10 μg mL−1 (Figure 7d). However, the
Figure 6 The concentration-dependent inhibition of single and dual antibody conjugates (from 1.25 to 10 μg mL−1) on the adhesion
of colon cancer cell lines to Fn-coated substrate. a, SW480 cells; b, LoVo cells; c, SW620 cells.
Figure 7 Inhibition by single and dual antibody conjugates on the hetero-adhesion between colon cancer cell lines and HUVECs
concentration-dependently (1.25 to 10 μg mL−1). a-c, The conjugates showed the different capability in interfering with the adhesion of
cancer cell lines to HUVECs. a, LoVo cells; b, SW480 cells; c, SW620 cells. d, Representative fluorescence images of Rhodamine 123-labeled SW480
cells that adhered to HUVECs when they were treated with different concentrations of G6-5A-5S conjugate.
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ferent colon cancer cell lines and the capability of single and
dual antibody conjugates was also different. It seemed that
conjugates displayed the stronger capability to interfere the
adhesion between SW620 cells and HUVECs in comparison
with the adhesion between other two cell lines and
HUVECs. The maximum adhesion percentage of SW620,
LoVo, and SW480 by the G6-5A-5S conjugate (10 μg mL−1)
was 38.60%, 61.11%, and 63.25%, respectively (Figure 7a-c).
G6-5A and G6-5A-5S conjugates were superior to G6-5S
conjugate in interfering the adhesion of colon cancer cells to
HUVECs. The adhesion of SW620 cells to HUVECs was re-
duced by 73.68% (G6-5A), by 58.19% (G6-5S), and by
61.40% (G6-5A-5S), respectively, at the same concentration
of 10 μg mL−1 (Figure 7c). The different anti-adhesion cap-
ability of the conjugates to each cancer cell line might con-
tribute to the selection of the appropriate conjugate as the
specific target for preventing cancer metastasis.
Discussion
AntiEpCAM and antiSlex collectively-coated dendrimer
conjugates were synthesized, for the first time, by employing
the surface coating technology [20,43]. The successful sur-
face functionalization was demonstrated both by UV spectra
and fluorescence images. FSEM measurement also showed
the morphology and size of the antibody-conjugated dendri-
mers (Figure 1). The average size of G6 PAMAM dendrimer
is about 7 nm. After conjugation with antibody, the size of
the PAMAM dendrimer quickly grew to 100 nm. The incre-
ment in size may be attributed to the increased numbers of
the dual antibodies conjugated. Moreover, two different anti-
bodies with the different size, specie, character and charge
may also result in the high variance in coating technique
and particle size.
Compared to the reported single antibody-coated den-
drimers [44,45], dual ones played the synergistic effects in
biological functions [46]. After excluding the non-specific
binding and cell autofluorescence with the isotype con-
trols, whatever to the adherent or suspensory cells, PE-
5A-G6-5S-FITC conjugate displayed the specific recogni-
tion and binding affinity (Figures 2 and 3), which might be
attributed to the antiEpCAM/EpCAM and antiSlex/Slex
double interactions. The conjugate could be internalized
into cytomembrane and cytoplasm not organelles with the
concentration increased or incubation time prolonged
(Figure 2, Additional file 1: Figure S2), which might be
caused by the cell endocytosis and the enhanced perme-
ability and retention (EPR) effects of nanomaterials. The
interactions between chemotherapeutics and cancer cells
were studied by us [10,29,47], so we have a good under-
standing of the molecular characterization of cancer cells.
Though dendrimers with carboxyl ending groups were
reported to be less toxic and more compatible than den-
drimers with amino terminal groups [48,49], whetherdendrimers coated with antiEpCAM and/or antiSlex af-
fected the activity of captured cells was investigated. Our
studies indicated that G6-5A and G6-5A-5S conjugates
decreased the viability of colon cancer cell lines (especially
SW620 cells) more significantly than G6-5S conjugate
(Figure 4). We further explored the regulation mechanism
by which G6-5A-5S conjugate blocked the cell cycle and
reduced the cellular MMP in a modest concentration-
dependent way (Figure 5). The result about cell activity
regulation was in agreement with what we have previously
reported [46,50]. Taken into account that the interaction
between Slex and E-selectin mediated the adhesion of
CTCs to endothelial cells, the intervention effects of the
conjugates were further explored. Adhesion assays showed
that both single and dual antibody conjugates effectively
inhibited the hetero-adhesion between each colon cancer
cell line and HUVECs/Fn-coated substrates (Figures 6
and 7). G6-5A and G6-5A-5S conjugates had the better
anti-adhesion effects than G6-5S conjugate. In compari-
son with SW480 and LoVo cell lines, SW620 cells were
more significantly affected by the conjugates, indicating
that antiEpCAM/EpCAM interaction played the critical
roles in the binding, regulation and adhesion processes
(Additional file 1: Figure S1). Superior to the detection
function, the dual biological functions of dual antibody-
coated nanomaterials, including anti-proliferation and anti-
adhesion effects, might interfere the critical points of
initiating cancer metastasis.
Conclusions
In conclusion, the present study firstly synthesized the dual
antibody-coated dendrimers with or without fluorescence la-
beling, and fully characterized their physicochemical proper-
ties. The dual antibody conjugates bound or captured the
colon cancer cell lines with the enhanced affinity and specifi-
city, and exhibited the superiority to their single counter-
parts in the restraint of cell activity and in the inhibition of
the hetero-adhesion of cancer cells to endothelial cells.
These newly-found biological functions of the re-engineered
nanomaterials with antibodies may aid in designing new
strategy to effectively prevent cancer metastasis by targeting
the biomarkers-abundant cancer cells.
Materials and methods
Synthesis and characterization of antiEpCAM- and
antiSlex- coated dendrimer conjugates with or without
fluorescence labeling
To investigate the dual roles of dendrimer-antibody
conjugates in cancer metastasis prevention, PAMAM
dendrimers with the ethylenediamine core [generation 6
(G6), theoretical MW 624,00 Da] provided by Shandong
Weihai Chenyuan New Silicone Materials, Co. Ltd were
firstly surface-modified and sequentially conjugated
with two fluorescence or non fluorescence-labeled
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ends of 256 (100 mg, 1.60 μmol) were dissolved in 2 mL
DMSO, and respectively reacted with 410 mg succinic an-
hydride (SA) (4.1 mmol, ten molar excess) under vigorous
stirring overnight. The obtained CC G6 dendrimers were
dialyzed against DDI water to remove the unreacted mole-
cules as well as organic solvents before lyophilization.
The dual antibody-conjugated dendrimer conjugate was
synthesized by employing the 1-ethyl-3-(3-dimethylamino-
propyl) carbodiimide (EDC) catalytic method and desig-
nated as G6-5A-5S based on the reaction molar ratio of 1
dendrimers to 5 antiEpCAM to 5 antiSlex. AntiSlex
(MW150KDa), IgG/IgM-FITC, antiEpCAM-PE were pro-
vided by BD company, and antiEpCAM (MW150
KDa) was purchased from Sigma-Aldrich and Abcam
(Hong Kong) Ltd. CC G6 dendrimers (0.55 μg, 7.9 pmol)
dissolved in 2 mL phosphate-buffered saline (PBS) were
activated using EDC (75.8 ng, 395.3 pmol, 50 molar ex-
cess) and N-hydroxysuccinimide (NHS) (45.5 ng, 395.3
pmol, 50 molar excess) at room temperature for 1 h. The
activated dendrimers were reacted with the combined
antiEpCAM (39.5 pmol, 5 molar excess) and antiSlex
(39.5 pmol, 5 molar excess) under vigorous stirring over-
night. The single antibody-coated dendrimer conjugates
were similarly synthesized and denoted as G6-5A and G6-
5S. There were approximately two aEpCAM molecules in
one G6-5A conjugate and six aSlex in one G6-5S conju-
gate according to the UV analysis. The fluorescence-
labeled dual antibody conjugate PE-5A-G6-5S-FITC was
also synthesized and designated following the similar pro-
cedure just by using antiEpCAM-PE and antiSlex-FITC
(antiSlex and IgG/IgM-FITC were used together) antibodies,
instead. The activated CC G6 dendrimers were reacted with
antiSlex-FITC for 12 h, then with antiEpCAM-PE for an-
other 12 h. All the reactions were conducted under vigorous
stirring overnight in dark. Finally, all the conjugates were
purified via dialysis (10,000 MWCO) against DDI water
overnight before lyophilization. Dendrimers with large sur-
face functional groups were almost able to assemble with all
of the antibodies as one entity at the above designed molar
ratios. Transmembrane dialysis was used to remove the in-
termediates and small molecules.
The presence of antibody or fluorescence-labeled antibody
onto the dendrimer surface was respectively confirmed by
the UV absorption value at λ220 nm (Quawell 5000 UV–vis
Spectrophotometer, America) and the merged fluorescence
intensity at FITC λex 488 nm, λem 500–535 nm and PE λex
568 nm, λem 560–660 nm (Olympus FluoView 1000). The
morphological property and particle size of G6-5A-5S con-
jugate were determined by FSEM measurement.
Cell culture
Human colorectal carcinoma cell lines including SW480,
SW620 and LoVo were purchased from the Type CultureCollection of the Chinese Academy of Sciences, Shanghai,
China and kept in a minimal number of passages, then
cultured in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal calf serum (FCS) and 1% penicillin/
streptomycin (P/S). HUVECs were obtained from the
fresh human umbilical cords of new-born babies with
1 mg mL−1 of collagenase in PBS and cultured by us with
M199 medium supplemented with 20% fetal bovine serum
(FBS), 100 μg mL−1 endothelial cell growth supplement
(ECGS), 50 μg mL−1 heparin sodium and 1% P/S in a cul-
ture flask coated with 0.2% gelatin after some necessary
pretreatment [10,51]. All the cell lines above were grown
in a humidified atmosphere of 5% CO2 at 37°C for the
subsequent experiments. HUVECs were used for no more
than six passages.
Flow cytometric procedures
A Becton Dickinson (BD) multiparametric fluorescence-
activated cell sorting (FACS) Aria III with laser excita-
tion set at 488 was used for flow cytometric analysis.
According to the forward versus side scatter histograms,
gating strategy was used to set P1 gate for determining
the target colon cancer cell lines. Fluorescence signals
derived from PI (or PE) and DiOC6(3) (or FITC) were
respectively detected through 585 and 530 nm bandpass
filters. Side angle scattered light (SSC) versus PI histo-
gram displayed the cell cycle distribution, SSC versus PE
(or FITC) histogram showed the expression levels of
biomarkers, SSC versus DiOC6(3) histogram revealed
the cellular MMP, and PE versus FITC dot plots showed
the captured cell numbers by the synthesized conjugate.
All the data were acquired based on the collected 10,000
cells satisfying the light scatter criteria and analyzed
using the BD FACS Diva software provided with the
system.
CTCs binding and capture assays
To explore the binding and capture capability of
fluorescence-labeled dual antibody conjugate PE-5A-G6-
5S-FITC at various concentrations (0, 10, 20 μg mL−1)
to the adherent and suspensory colon cancer cell lines,
the optimal incubation time was in advance determined
according to the analysis of time-response cell capture
assay shown in Additional file 1. The preliminary result
showed that 1 h-binding time was sine qua non for the
quick and efficient cell capture.
Binding to the adherent cells
Cell lines at the density of 105/mL were cultivated on
35 mm dishes with glass coverslips in the bottom, and indi-
vidually treated with PBS containing 1% bovine serum
albumin (BSA) (1% PBSA) for 30 min. After 1 h of co-
incubation with PE-5A-G6-5S-FITC conjugate at various
concentrations (0, 10, 20 μg mL−1) in a humidified
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PBS to remove the unbound conjugate, and fixed with sta-
tionary liquid (Vmethanol:Vacetone = 7:3) for 1 min, then stained
with 10 μg mL−1 of nuclei stain dihydrochloride (DAPI) so-
lution for 15 min. Finally, cell lines were covered with
serum-free medium for images taken by an Olympus Fluo-
View 1000 laser confocal microscope respectively in the
channel of DAPI, Alex Fluor 488 and 568.
Capturing the suspensory cells
To evaluate the efficiency of PE-5A-G6-5S-FITC conju-
gate at capturing the colon cancer cell lines, SW620 and
LoVo cell lines at the density of 106/mL were suspended
in each tube. Cell lines were treated with 1% PBSA, then
with 20 μg mL−1 of PE-5A-G6-5S-FITC conjugate for 1 h
at 37°C water bath. Cell lines without the treatment of
conjugate were incubated with immunoglobulins labeled
with PE or FITC in the similar way as isotype controls.
After washing and centrifugation, the unbound conjugates
or antibodies were abandoned. Cell lines suspended with
PBS buffer were directly analyzed on a BD FACS Aria III
analyzer with laser excitation set at 488 nm or further
stained with Hoechst 33258 (labeling the nucleus) for
analysis with a fluorescence inverted microscope (Axio
Observer A1, Zeiss, Germany).
Restraining the captured CTCs for preventing cancer
metastasis
Cell viability
To investigate how the single and dual antibody conju-
gates (G6-5A, G6-5S and G6-5A-5S) affected the cell
proliferation, MTT analysis was conducted as we previ-
ously described. The effect of completely-carboxylated
G6 dendrimers on cell activity was also tested. Cell lines
at the density of 5 × 103-1 × 104 cells/mL were cultivated
on the 96-well plates with 1640 medium. When grew in
the confluence of 70%-80%, cell lines were individually
exposed to the conjugates at various concentrations
(0, 1.25, 2.5, 5, 10, 15, 20 μg mL−1) for 48 h. Then,
100 μL of serum-free medium containing 1 mg mL−1
MTT solution was added to incubate for another 4 h. Fi-
nally, the supernatant was aspirated and 150 μL of
DMSO was added to each well to dissolve the water-
insoluble blue formazan. The viability of each cell line
induced by the conjugates was determined based on the
optical absorption value at the wavelength of 570 nm
(A570 nm) and expressed as A570 nm of the treated group
divided by that of the control group.
Cell cycle distribution
To further discuss the effects of the antibody conjugates
(e.g., G6-5A-5S) on the cell population distribution in
every phases (G0/G1, S, and G2/M), PI staining experi-
ment was performed at 37°C as the kit instructions. Celllines were cultivated in 6-well plates overnight, and incu-
bated with various concentrations of G6-5A-5S conjugate
(0, 10, 20 μg mL−1) for 48 h. Then cell lines were trypsi-
nised and washed with ice-cold PBS for three times. After
fixed with 70% ice-cold ethanol overnight at −20°C, cell
lines were washed and stained with PI solution at 37°C for
15 min. Finally, data acquisition and analysis were per-
formed on a BD FACS Aria III flow cytometer and DNA
integration software mflt32, respectively.Cellular MMP
Depolarization of cellular MMP usually predicts the starting
of cell apoptosis. In this assay, DiOC6(3) (a lipotropy cat-
ionic fluorescent dye) staining was used to determine the
change of MMP in colon cancer cell lines. Increment of
fluorescence intensity with the accumulation of DiOC6(3) in
mitochondria was accompanied with the descent of MMP.
After exposure to the antibody conjugates (e.g., G6-5A-5S)
at various concentrations (0, 10, 20 μg mL−1) for 48 h, cell
lines were trypsinized and collected after centrifugation.
500 μL of DiOC6(3) (2 nM) working solution was individu-
ally added into each tube, and kept at 37°C water bath for
20 min. The cellular MMP (Δψm) was finally assessed ac-
cording to the fluorescence intensity of DiOC6(3) examined
by the flow cytometry (BD FACS Aria III).Inhibiting the adhesion of captured CTCs to endothelial
cells for preventing cancer metastasis
Blocking the adhesion of cancer cells to Fn-coated substrates
Adhesion of CTCs to extracellular matrix (ECM) was a
critical step in the process of cancer metastasis. Colon
cancer cell lines were usually used as CTC models. In
cell adhesion assays, CC G6 dendrimers were used as
the control. Fn-coated substrates were prepared as the
ECM to test the capability of single and dual antibody
conjugates (G6-5A, G6-5S, G6-5A-5S) in interfering the
adhesion of colon cancer cell lines to ECM. First of all,
10 ng mL−1 of Fn was pre-coated on the substrates of
96-well plate overnight, then discarded and sealed up
with 2% PBSA for 30 min. 100 μL of the mixtures of cell
lines and conjugate at various concentrations (0, 1.25,
2.5, 5, 10 μg mL−1) were added onto each well for 1 h of
incubation. The post-processing was similar to that de-
scribed in MTT assay. 100 μL of serum-free medium
containing 1 mg mL−1 MTT solution was used for an-
other 4 h. After the supernatant was aspirated, 100 μL of
DMSO was added to each well to dissolve the water-
insoluble blue formazan. The optical density was read
on an ELISA reader at a wavelength of 570 nm to deter-
mine the abilities of the conjugates to interfere with the
adhesion. The relative adhesion (%) was finally evaluated
by the A570 nm in the treated group compared to that in
the control group.
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Adhesion of CTCs to vascular endothelium was another
crucial starting point of cancer metastasis. HUVECs in-
stead of vascular endothelial cells were used for adhesion
assay in vitro. After grew in the confluence of 100% on the
24-well plates, HUVECs were pre-treated with 1 ng mL−1
cytokine IL-1β for 4 h followed by individually incubated
with the mixture of rhodamine 123-labeled colon cancer
cell lines and single or dual antibody conjugates (G6-5A,
G6-5S, G6-5A-5S) at various concentrations (0, 1.25, 2.5,
5, 10 μg mL−1) for 1 h. After removal of the non-adhered
cells with PBS washing, ten visual fields were randomly se-
lected and taken images by a fluorescence inverted micro-
scope (Axio Observer A1, Zeiss, Germany). The capability
of the conjugates in inhibiting the adherence of cancer cell
lines to HUVECs was determined by counting the num-
bers of fluorescence-labeled cells that adhered to HUVECs
in sample groups relative to those in the control group.
Statistical analysis
Every experiment was performed independently and re-
peated at least three times. Data were expressed as the
means ± standard deviations (SD). Statistical analysis was
done by Student’s t-test and one-way analysis of variance
(One-ANOVA). Multiple comparisons of the means were
made through One-ANOVA analysis and demonstrated by
the least significance difference (LSD) test (IBM SPSS Statis-
tics 19.0). The symbol of * and ** represented the compari-
son between sample and control, while # and ## represented
the comparison between any two samples. A probabil-
ity value of <0.05 was considered significant (* and #),
and <0.01 was considered extremely significant
(** and ##).
Additional file
Additional file 1: Biomarkers expression and Time-response cell
capture.
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